Dr. Angelo academic background spans across the fields of physics, biochemistry, electrical engineering, and medicine. During his residency he became interested in developing novel methods for immunohistochemical multiplexing using mass spectrometry leading to the development of MIBI during his postdoctoral work in the Nolan lab at Stanford University. Dr. Angelo is now interested in optimizing MIBI and other mass reporter-based technologies further with the goal of identifying new transcriptional and translational signatures in solid tissue malignancies, and in allergic and other immunological disorders, that can be used to improve clinical diagnosis and treatment.
Dr. Bendall’s is an expert in protein biochemistry, mass spectrometry, and stem cell biology, and single cell analysis. His lab creates new methods for single cell proteomics that are applied to human stem cell biology, cancer immunology, and neurodegenerative disease. These include his pioneering work in ICP-MS based flow cytometry (CyToF) for studying the regulation of the human hematopoietic immune system in health and disease as well as leveraging multiplexed ion beam imaging for human neuropathology. His lab continually uses the collection of these tools for correlating single cell pathobiology with clinical outcomes in retrospective studies.
Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 180 research articles and is the holder of 20 US patents, and has been honored as one of the top 25 inventors at Stanford University. Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.
Dr. Fienberg is a co-founder and the CEO of Ionpath. Prior to Ionpath he contributed to the development of the MIBI technology as a Postdoctoral Scholar in the Department of Pathology at Stanford University. Dr. Fienberg has a PhD in Microbiology and Immunology from Stanford University, an MSc in Evolutionary Biology from the University of Basel, where he was a Fulbright Scholar, a BS in Biological Sciences and a BA in English Literature, both from Stanford University.